LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Heron Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.92 -4.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.92

Max

2

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-1M

2.6M

Pardavimai

-1.9M

39M

Pelnas, tenkantis vienai akcijai

0.013

Pelno marža

6.773

Darbuotojai

122

EBITDA

-5M

3.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+210.95% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-28M

323M

Ankstesnė atidarymo kaina

6.87

Ankstesnė uždarymo kaina

1.92

Naujienos nuotaikos

By Acuity

35%

65%

125 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Heron Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-13 22:33; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefonica Ecuador for $380 Million

2025-06-13 23:50; UTC

Įsigijimai, susijungimai, perėmimai

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

2025-06-13 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

2025-06-13 23:09; UTC

Įsigijimai, susijungimai, perėmimai

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

2025-06-13 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

2025-06-13 22:18; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefonica Ecuador for $380M

2025-06-13 22:04; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Better Data Facilitate Investments In Oil Patch -- Market Talk

2025-06-13 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

2025-06-13 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Bunge: Outside Date Extended to July 3

2025-06-13 21:35; UTC

Įsigijimai, susijungimai, perėmimai

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

2025-06-13 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Bunge Gets Mexico Approval for Viterra Deal

2025-06-13 21:32; UTC

Įsigijimai, susijungimai, perėmimai

Bunge Gets China Approval for Viterra Deal

2025-06-13 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-13 20:45; UTC

Įsigijimai, susijungimai, perėmimai

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

2025-06-13 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- Update

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

2025-06-13 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2025-06-13 19:12; UTC

Rinkos pokalbiai

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

2025-06-13 19:04; UTC

Rinkos pokalbiai

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

2025-06-13 18:54; UTC

Rinkos pokalbiai

Correction to Gold Settles Market Talk

2025-06-13 18:01; UTC

Rinkos pokalbiai

Gold Settles at Record High -- Market Talk

2025-06-13 17:40; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

2025-06-13 17:21; UTC

Rinkos pokalbiai

Dollar Index, Commodities Rise -- Market Talk

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

2025-06-13 17:02; UTC

Įsigijimai, susijungimai, perėmimai

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

2025-06-13 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Heron Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

210.95% į viršų

12 mėnesių prognozė

Vidutinis 6.25 USD  210.95%

Aukščiausias 9 USD

Žemiausias 4 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Heron Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

4

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

2.0001 / 2.42Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

125 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.